Welcome to BioSeeker Group!

Triple Analysis: Lymphoma, Pancreatic Cancer and Apoptosis

Additional Information

Published Date Mar 1, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3674
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lymphoma, Pancreatic Cancer and Apoptosis in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Pancreatic Cancer and by the mechanism/target/effect of Apoptosis.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Pancreatic Cancer and Apoptosis.

    To find out more about Triple Analysis: Lymphoma, Pancreatic Cancer and Apoptosis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Pancreatic Cancer and Apoptosis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Pancreatic Cancer and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part II: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part III: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part II: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

Part III: Apoptosis
5.1 The Scope of this Report 33
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660
9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601
Disclaimer 1602
11 Drug Index 1603
12 Company Index 1611
Figures: Includes 7 Figures
Tables: Includes 315 Tables
Total Number of Pages: 1,617

This Report Includes the Following Companies:
4SC
AB Science
Abbott
Abiogen
Access
Active Biotech
Advanced Life Sciences
Advantagene
Advaxis
AEgera
AEterna Zentaris
Affimed Therapeutics
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alfa Wassermann
Alfacell
Allos Therapeutics
Alnylam
Ambit Biosciences
Ambrilia Biopharma
Amgen
Anadys Pharmaceuticals
Anaphore
Anavex Life Sciences
Antisense Pharma
Antisoma
Anza Therapeutics
Aphios
Apogee Biotechnology
Apogenix
ApopLogic Pharmaceuticals
Apotex
Apricus Biosciences
Ardea Biosciences
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Avila Therapeutics
Basilea Pharmaceutica
Bayer
Benitec
Betapharma
BioAlliance Pharma
BioAxone
Biocad
Biocon
BioCryst Pharmaceuticals
Biogen Idec
BioInvent
Biolex
BioLineRx
Biomas
Bionovo
BioNumerik
BioSante
BioVex
Boehringer Ingelheim
Borean Pharma
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Cancer Advances
Cancer Research Technology
CDG Therapeutics
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celltrion
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
ChemoCentryx
Chlorogen
Chroma Therapeutics
Cleveland BioLabs
CombinatoRx
CompleGen
Cornerstone Pharmaceuticals
Coronado Biosciences
Critical Outcome Technologies
CritiTech
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Dendreon
DeveloGen
Dr Reddy’s
Dynavax Technologies
EGEN Inc
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Epizyme
Erimos
Esperance Pharmaceuticals
Exelixis
Favrille
FibroGen
Forma Therapeutics
Galectin Therapeutics
Gemin X Biotechnologies
Genencor
Genentech
Genmab
GenPat77
Genta
GenVec
Genzyme
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
Glycotope
GPC Biotech
Green Cross
Harbor BioSciences
Hayashibara
Heber Biotec
HemaQuest
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Idera Pharmaceuticals
IGF Oncology
ImmunoCellular Therapeutics
ImmunoGen
Immunomedics
ImmuPharma
Immutep
Inex
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Intradigm
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
ISU ABXIS
Italfarmaco
Johnson & Johnson
Kadmon
Kalypsys
Keryx Biopharmaceuticals
Kinex
Kissei
Kyowa Hakko Kirin
Leo
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
MBiotec
Meda
MediGene
MedImmune
Medisyn Technologies
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novelix
Novogen
Noxxon
Nycomed Pharma
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncozyme Pharma
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Patrys
Pepscan Therapeutics
Pfizer
Pharmacyclics
PharmaMar
Pharmexa
Pharminox
Philogen
Pierre Fabre
Piramal
Plexxikon
Portola Pharmaceuticals
ProMetic Life Sciences
ProNAi Therapeutics
Protgen
QLT
Ras Therapeutics
Reata Pharmaceuticals
Regeneron
Regulon
Reliance Life Sciences
RESprotect
Rexahn
Rigel
Rosetta Genomics
Rottapharm Madaus
Samyang
Sanofi
Sanofi-Aventis
Santaris Pharma
SBI Biotech
SBIO
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Senesco Technologies
Shire
Sigma-Tau
SRI International
SuperGen
SuppreMol
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Synageva BioPharma
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Tau Therapeutics
Taxolog
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Tigris Pharmaceuticals
Titan Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
Trion Pharma
UMN Pharma
Vaccinex
ValiRx
VaxOnco
VBL Therapeutics
Velacor Therapeutics
VentiRx Pharmaceuticals
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
Viragen
Viralytics
ViroMed
ViroTarg
VM Discovery
XBiotech
Xencor
Xerion
Yakult Honsha
YM BioSciences
Zenotech
Zenyaku Kogyo
Zeria
A Shortlist of Drugs Included are:
131I-tositumomab
AEG-35156
aflibercept
AGS-1C4D4
alemtuzumab
alvocidib
AME-133
amrubicin hydrochloride
APG-101
apricoxib
ARC-100
ARQ-197
AS-101
AS-1411
bardoxolone methyl
belinostat
bevacizumab
bexarotene
bortezomib
bosutinib
brentuximab vedotin
brivanib alaninate
brivudine
BZL-101
Cabozantinib
canfosfamide hydrochloride
capecitabine
catumaxomab
celecoxib
cenersen
cetuximab
CG-201
cilengitide
cintredekin besudotox
cixutumumab
cladribine
conatumumab
CPI-613
CRLX-101
crolibulin
dalotuzumab
dasatinib
denileukin diftitox
dinaciclib
docetaxel
doxorubicin
dulanermin
E-7820
elliptinium acetate
eniluracil
enzastaurin hydrochloride
epirubicin
erlotinib
everolimus
fosbretabulin tromethamine
galiximab
ganitumab
gataparsen
gefitinib
GSK-1120212
GT-111
GV-1001
GVAX
HBP-347
HE-3235
ibritumomab tiuxetan
icotinib hydrochloride
idronoxil
imatinib mesilate
imetelstat
IMP-321
inotuzumab ozogamicin
interferon (alpha)
interferon (alpha2b)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
ipilimumab
irinotecan
irinotecan hydrochloride
kahalalide F
KD032
L19-IL2
lapatinib ditosylate
lestaurtinib
LipoVIL12
litronesib
lonaprisan
lumiliximab
mapatumumab
masitinib
MetXia
mitoxantrone
MKC-1
mocetinostat
motexafin gadolinium
nadroparin
navitoclax
nimotuzumab
noscapine
obinutuzumab
oblimersen sodium
ofatumumab
olaparib
ON-01910
Oncohist
OTS-102
P-276-00
paclitaxel
PancAtak
panobinostat
pasireotide
pasireotide LAR
PAT-SC1
pazopanib hydrochloride
PBI-1402
PCI-24781
PCI-27483
pemetrexed disodium
pentamidine isethionate
perifosine
pixantrone
plitidepsin
pralatrexate
PX-12
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
razoxane
Reditux
retaspimycin
Rexin-G
rhIFN-alpha
rituximab
romidepsin
RX-0201
sagopilone
seliciclib
selumetinib
siltuximab
sobuzoxane
sorafenib tosylate
SPC-2996
ß-lapachone
SU-6668
sunitinib malate
talminogene laherparepvec
tegafur + uracil
temsirolimus
teniposide
terameprocol
tigapotide triflutate
tigatuzumab
tipifarnib
TL-32711
tocilizumab
trabedersen
trastuzumab
triciribine phosphate
TRU-016
TS-1
tucotuzumab celmoleukin
varlitinib
vismodegib
volasertib
volociximab
vosaroxin
WX-671
XL-147
XL-647
Z-360
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Pancreatic Cancer and Apoptosis.
    To find out more about Triple Analysis: Lymphoma, Pancreatic Cancer and Apoptosis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Pancreatic Cancer and Apoptosis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Lung Cancer, Prostate Cancer and Peptides
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Prostate Cancer and by the compound strategy of Peptides. Learn More


Triple Analysis: Breast Cancer, Colorectal Cancer and Melanoma
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Colorectal Cancer and Melanoma. Learn More

Other selected research from the 'Oncology' category:


Hematological Cancers - A Therapeutic & Competitive Insight
BioSeeker Group has studied the progress of 125 of the most prominent drugs in development for the treatment of hematological cancers. This extensive 190+ pages report not only describes and analyzes the latest years of progress in lymphoma and leukemia, it also provides an insight and framework to understand this complex field. Learn More


Triple Analysis: Breast Cancer, Leukemia and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Leukemia and by the mechanism/target/effect of Angiogenesis. Learn More